AD/PD 2025: Further evidence for efficacy of TauRx's LMTX, despite lack of true placebo comparator

AD/PD 2025: Further evidence for efficacy of TauRx's LMTX, despite lack of true placebo comparator
At the AD/PD 2025 conference, TauRx Therapeutics presented new data from the Phase III LUCIDITY trial confirming LMTX efficacy in treating mild cognitive impairment and Alzheimer's. Challenges in placebo-controlled trials due to drug properties were addressed by analyzing data from other Alzheimer's trials.